It’s Not You, It’s SOSA: A Case Study on Breaking Up With an FDA-Cleared Susceptibility Testing System’s Oxacillin Results for Staphylococcus spp. Other Than S. aureus and S. lugdunensis
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac421
Abstract: Abstract Background In 2021, the Clinical and Laboratory Standards Institute revised its susceptible oxacillin minimum inhibitory concentration (MIC) breakpoint for Staphylococcus spp. other than S. aureus and S. lugdunensis (SOSA) from ≤0.25 to ≤0.5 µg/mL. Here,… read more here.
Keywords: pbp2a testing; aureus lugdunensis; staphylococcus spp; cefoxitin ... See more keywords
2422. Efficacy of Cefoxitin for the Treatment of Urinary Tract Infection (UTI) Due to ESBL-Producing E. coli and K. pneumoniae Isolates
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.2075
Abstract: Abstract Background Cefoxitin has a good in vitro activity and stability in resistance to hydrolysis by ESBLs, and is a good candidate for the treatment of urinary tract infection (UTI). However, data are scarce regarding… read more here.
Keywords: treatment urinary; urinary tract; treatment; cefoxitin ... See more keywords
Development of a new pharmacokinetic model for target-concentration controlled infusion of cefoxitin as a prophylactic antibiotic in colorectal surgical patients.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.14883
Abstract: AIMS There are several limitations to the existing method of administering cefoxitin as a prophylactic antibiotic, and the limitations may be overcome by applying the target-concentration controlled infusion (TCI) method. Population pharmacokinetic parameters are required… read more here.
Keywords: pharmacokinetic model; cefoxitin; method; surgical patients ... See more keywords